Forget buy-to-let! I’d buy these 2 FTSE 100 stocks to retire early

I think these two FTSE 100 (INDEXFTSE:UKX) shares could offer improving growth outlooks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

The outlook for the buy-to-let industry may be more positive following the general election. Fears surrounding a Jeremy Corbyn-led government and potential changes to taxation may mean that house prices make gains in the short run.

However, in the long run, the FTSE 100 could outperform buy-to-let investments. It appears to offer superior value for money, greater diversity and a range of stocks with sound growth strategies.

With that in mind, here are two FTSE 100 shares that could deliver impressive long-term total returns. They could help to bring your retirement date a step closer.

AstraZeneca

Recent updates from pharma stock AstraZeneca (LSE: AZN) have provided evidence of the scale of its turnaround. While in previous years it has struggled to generate top- and bottom-line growth, its sales and profitability are now growing at double-digit rates. This trend could continue over the medium term as the business benefits from the major investment it has made in its pipeline over recent years.

Risks facing UK investors may have subsided following the recent general election. However, global growth uncertainties remain in place. For example, political risk in the US and China may continue to be high in 2020, while tariffs could act as a drag on global GDP growth. Therefore, AstraZeneca’s defensive characteristics could help it to outperform many of its FTSE 100 peers. Its reduced dependency on the wider economy’s performance may mean that it becomes more popular among investors.

As such, now could be the right time to buy a slice of the company. Its improving financial performance and increasing favour among investors may mean that it outpaces house price growth in the long run.

Bunzl

One FTSE 100 share that is being negatively impacted by an uncertain global macroeconomic outlook is Bunzl (LSE: BNZL). The international distribution and services company recently released a trading update that showed the slowing sales trend from earlier in 2019 has continued.

For example, in its third quarter, the company reported a rise in sales at constant exchange rates of just 0.5%. When the impact of acquisitions is excluded, its sales declined by 1%.

Looking ahead, Bunzl has an active acquisition pipeline. It has already spent £100m on acquisitions this year, and is likely to continue to add new businesses to its portfolio over the medium term. They could catalyse its financial performance and help to offset an uncertain trading period for the business.

With a solid track record of growth that includes five continuous years of increasing earnings, Bunzl could offer long-term growth potential. Following its 12% share price decline in the last year, now could be the right time to buy a slice of it while it trades on a lower valuation. It may fail to recover significantly in the short run, but could offer turnaround potential in the coming years.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »